Phillips-Medisize Corporation (the “Company”) today announced that it has acquired Medicom Innovation Partner (“Medicom”), a leading provider of device strategy, product design and development services with particular focus on personal connected health drug delivery device solutions to meet the needs of the rapidly growing biopharma and specialty pharmaceutical markets. Terms of the transaction were not disclosed.
Through this acquisition, Phillips-Medisize will bolster its leading position in drug delivery device solutions. Together, the combined company will have over 500 engineers across facilities in Hudson, WI; Mountain View, CA; Hillegom, Netherlands; Struer, Denmark; Cambridge, United Kingdom; and Suzhou, China. The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable and inhalation device innovation service solutions for biopharma customers, including early device strategy, human factors engineering, product development, clinical production, full scale production and integrated supply chain management.
Matt Jennings, Chairman, CEO and President of Phillips-Medisize, said, “This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalized oncology markets that need these products and reinforces our leading position in drug delivery device solutions. Medicom’s impressive solutions, 25 years of expertise and 100+ state-of-the-art technology accelerators, coupled with Phillips-Medisize’s scale in design to manufacturing of high to low volume production drug delivery devices, will provide customers with end-to-end integrated service solutions, resulting in increased speed to market. We are excited to welcome the talented Medicom team to Phillips-Medisize and look forward to working together to deliver services and solutions that improve patient compliance and outcomes.”
“We are pleased to partner with Phillips-Medisize, a recognized global leader with an impressive track record of delivering a broad and deep set of capabilities to customers. We are confident that customers of both companies will benefit from an enhanced offering of end-to-end integrated service solutions across a global network while continuing to receive the same best-in-class service that they have come to expect,” said Morten Nielsen, CEO of Medicom. “Importantly, our companies are culturally aligned and we share the same deep- rooted passion for innovation which improves our customers’ competitiveness.”
Medicom will continue to be led by Mr. Nielsen and Medicom’s existing management team. Mr. Nielsen will report to Bill Welch, Phillips-Medisize’s Chief Technology Officer and global leader of preproduction services.